Generic Medicine Info
Indications and Dosage
Peptic ulcer
Adult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Maintenance dose to prevent the recurrence of duodenal ulcers: 1 g bid. Max: 8 g daily.

Chronic gastritis
Adult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Max: 8 g daily.

Prophylaxis of gastrointestinal haemorrhage from stress ulceration
Adult: 1 g 6 times daily. Max: 8 g daily.
Should be taken on an empty stomach. Take 1 hr before or 2 hr after meals.
Special Precautions
Patient w/ known conditions that may impair swallowing (e.g. recent or prolonged intubation, tracheostomy, dysphagia). Renal impairment. Pregnancy and lactation.
Adverse Reactions
Nervous: Headache, dizziness, drowsiness, insomnia, vertigo.
GI: Constipation, diarrhoea, nausea, vomiting, flatulence, indigestion, gastric discomfort, dry mouth.
Musculoskeletal: Back pain.
Dermatologic: Pruritus, skin rash.
Drug Interactions
May increase total body burden of Al w/ drugs that contain Al (e.g. Al-containing antacids). May reduce absorption of tetracyclines, ranitidine, ketoconazole, theophylline, phenytoin, cimetidine, ciprofloxacin, norfloxacin and digoxin.
Description: Sucralfate protects GI lining against peptic acid, pepsin and bile salts by binding w/ positively-charged proteins in exudates forming a viscous paste-like adhesive substance thus forming a protective coating.
Onset: 1-2 hr.
Duration: 6 hr.
Absorption: Minimally absorbed from the GI tract.
Distribution: Acts locally at ulcer sites; unbound in GI tract to aluminum and sucrose octasulfate.
Excretion: Mainly via urine.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Sucralfate, CID=121494085, (accessed on Jan. 31, 2020)

Store between 20-25°C.
ATC Classification
A02BX02 - sucralfate ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Anon. Sucralfate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 18/10/2017.

Buckingham R (ed). Sucralfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 18/10/2017.

Joint Formulary Committee. Sucralfate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 18/10/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Sucralfate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 18/10/2017.

Sucralfate Tablet (Actavis Pharma, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 18/10/2017.

Disclaimer: This information is independently developed by MIMS based on Sucralfate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
  • Kalpepsa
  • Lanpepsa
  • Mucogard
  • Peptovell
  • Profat
  • Ulcera
  • Ulcumaag
  • Ulsafate
  • Ulsidex
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in